Migraine Prophylaxis with Lisuride Hydrogen Maleate-A Double Blind Study of Lisuride Versus Placebo




This paper reports the results of a double-blind clinical trial of the antiserotonin compound Lisuride hydrogen maleate (LHM) in the prophylaxis of frequent and severe migraine. The study was conducted over a minimum period of three months. When judged according to reduction in frequency of attacks, LHM emerged significantly superior to placebo (p<0.05), though a higher rate of side effects was noted in the active treatment group. A high rate of placebo response (in keeping with other similar trials) was observed.It is concluded that LHM is significantly superior to placebo as a migraine prophylactic and its relative freedom from serious side effects suggests a useful role for the drug as an alternative to methysergide.